Published 2 days ago • loading... • Updated 7 hours ago

Employers face pressure to add coverage of Ozempic, other weight-loss drugs

Generic versions of Ozempic could be available in Canada by 2026, with four companies applying to Health Canada for permission to sell them, as reported by Health Canada.
Ozempic sales in Canadian pharmacies reached over $2.5 billion in 2023, making it the top-selling prescription drug in Canada, according to IQVIA.
Research shows that patients using semaglutide had a 52% higher risk of hair loss compared to users of Contrave, as noted by Mohit Sodhi from the University of British Columbia.
Novo Nordisk's patent for semaglutide in Canada expired in 2020, and their spokesperson stated that patent expiry is a natural part of the product lifecycle.

Insights by Ground AI

Does this summary seem wrong?

45 Articles

All

Left

Center

Right

Watauga Democrat

Ask the doctors: GLP-1 microdosing is experimental and unauthorized

Dear Doctors: I’m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’m wondering about Ozempic. How does that work? I’m also hearing about people doing Ozempic microdosing. Do you know…

12 hours ago·Calhoun, United States

Read Full Article

The Business Journals

Employers face pressure to add coverage of Ozempic, other weight-loss drugs

Businesses are facing pressure on multiple fronts to coverage popular weight-loss drugs. The situation is nearing a flash point, but the stakes are high.

19 hours ago·United States

Read Full Article

CNBC

Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests

Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.

1 day ago·United States

Read Full Article

The Globe & Mail

Cheaper, generic versions of Ozempic could come to Canada as early as next year

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026

2 days ago·Canada

Read Full Article

thepilotnews.com

+31 Reposted by 31 other sources

Parker Waichman LLP Investigating Ozempic and Wegovy Vision Loss Claims

National Law Firm Accepting Cases for Victims Suffering from NAION (Eye Stroke) After Using Popular GLP-1 Medications

2 days ago·Plymouth, United States

Read Full Article

Santa Clarita Valley Signal

38 attorneys general urge FDA to offer protection from fake weight loss drugs

By Naveen Athrappully Contributing Writer The U.S. Food and Drug Administration must act to protect Americans from fake versions of GLP-1 weight loss and diabetes drugs such as Ozempic and Mounjaro and take “decisive action” against bad actors engaged in such trade, a letter from a bipartisan coalition of attorneys general from 38 U.S. states said. “My fellow attorneys general and I are urging the FDA to protect consumers from the growing thre…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year